Prostate neoplasm

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…

This study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…

This phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This early-phase trial is testing a new immunotherapy drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and tolerability, while also looking …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests a drug called REGN5678 in men with high-risk prostate cancer who will later have their prostate removed. The goal is to check the drug's safety and how it affects the cancer before surgery. About 42 men will take part in this early-phase trial at MD Anderson Canc…

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This study tests a new drug called AZD2265, which delivers radiation directly to prostate cancer cells. It is for people with a type of advanced prostate cancer that no longer responds to hormone therapy. The trial compares the new drug to standard treatments to see if it can slo…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This phase II trial tests whether adding bipolar androgen therapy (cycles of testosterone) to the standard Sipuleucel-T vaccine can boost the immune response in men with metastatic castration-resistant prostate cancer. About 26 participants will receive both treatments, and resea…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This Phase 3 trial tests whether adding the experimental drug mevrometostat to the standard drug enzalutamide can slow cancer growth better than enzalutamide alone. It involves 900 men with metastatic castration-resistant prostate cancer who have not yet tried certain hormone the…

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new robot-assisted surgery for localized prostate cancer that leaves the full length of the urethra intact. The goal is to help men regain urinary continence faster after prostate removal. About 60 men with early-stage prostate cancer will undergo the procedure…

This study tests whether adding darolutamide to standard treatments can help men with a certain type of advanced prostate cancer (mCRPC) live longer without their cancer getting worse. About 162 participants will receive either standard care alone or standard care plus darolutami…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has no…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can slow down cancer growth better than enzalutamide alone. It involves 1000 men with metastatic prostate cancer that still responds to hormone therapy. Participants will be…

This trial tests whether focal ablation—using extreme cold (cryotherapy) or high-intensity ultrasound (HIFU)—can effectively destroy prostate tumors while leaving healthy tissue unharmed. It enrolls men with early-stage, localized prostate cancer that shows up on MRI. The goal is…

This study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progre…

This early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effe…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This study tests a personalized approach to radiation therapy for men whose prostate cancer has returned after surgery. Instead of giving everyone the same treatment, doctors will adjust the plan based on how well the cancer responds to initial radiation. Those who respond well m…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This study tests a high-dose radiation implant (brachytherapy) for men whose prostate cancer returned after standard external beam radiation. About 30 participants will receive this targeted treatment to the exact spot of recurrence, identified by advanced MRI. The goal is to con…

This study tests whether early referral to a cardio-oncology specialist can lower heart risks in prostate cancer patients receiving long-term hormone therapy (ARPI). About 80 men with high-risk or advanced prostate cancer and additional heart risk factors will be assigned to eith…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This phase 2 study tests an oral drug called XL092 (Zanzalintinib) in 32 men with metastatic castration-resistant prostate cancer that has worsened after treatment with Lu-PSMA-617. Participants take one tablet daily at home. The main goal is to see how many men have their cancer…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a program designed to help men with prostate cancer manage their heart health while undergoing hormone therapy (ADT). The program involves two counseling sessions with a nurse or physician assistant to educate about cardiovascular risks and how to reduce them. Re…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This Phase 3 trial tests whether personalizing apalutamide treatment based on cancer aggressiveness can reduce fatigue and other side effects in men with prostate cancer who have detectable PSA after prostatectomy. About 120 participants will receive either standard therapy or a …

This study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…

This study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This phase 2 trial tests whether giving prostate cancer radiation in just 2 sessions is as safe and effective as the standard 5-session approach. About 100 men with low- or intermediate-risk prostate cancer will be randomly assigned to one of the two schedules. Both groups will u…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…

This study tests a new treatment called SYNC-T therapy (SV-102) for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 91 me…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This study tests a special scaffold placed during prostate removal surgery to help men regain bladder control. About 266 men will be randomly assigned to get the scaffold or standard care. The goal is to see if the scaffold reduces urine leakage and improves quality of life over …

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study is testing a new treatment called 4SCAR-PSMA T cells for people whose cancers have a specific marker called PSMA. The therapy involves collecting a patient's own immune cells, modifying them to better recognize and attack cancer cells, and infusing them back. Up to 100…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This study tests a new drug called tinengotinib combined with standard hormone therapies (abiraterone or enzalutamide) in 50 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to usual treatment. The goal is to see if the combination i…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…

This study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35…

This study tests whether taking darolutamide (a hormone-blocking pill) plus standard hormone therapy for 12 or 24 weeks before prostate removal surgery can reduce or eliminate cancer in men with high-risk localized prostate cancer. About 250 men in China will be randomly assigned…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests if men with metastatic hormone-sensitive prostate cancer who have a strong initial response to hormone therapy can safely take breaks from one of their medications (relugolix) to reduce fatigue. About 160 participants will either continue standard daily therapy o…

This study compares two treatments for low-to-intermediate risk prostate cancer: a new robotic surgery that removes part of the prostate through a single small incision, and high-intensity focused ultrasound (HIFU) that uses sound waves to destroy cancer cells. About 276 men will…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests a new way to deliver high-dose radiation to prostate tumors using real-time MRI guidance. It includes two groups: men whose prostate cancer has returned after prior radiation, and men with advanced cancer receiving standard external beam radiation plus this boost…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This early-stage trial tests a new drug called 177Lu-PSMA-VG01 in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has spread and stopped responding to hormone therapy. The drug is designed to deliver radiation directly to cancer cells, aiming to sh…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This phase 2 trial tests a two-step treatment for men with metastatic prostate cancer that no longer responds to standard hormone therapy. First, patients receive a combination of testosterone and an experimental drug called ZEN-3694, followed by a mix of enzalutamide and ZEN-369…

This study tests proton radiation therapy for men with prostate cancer that has returned or is at risk of returning after prostate removal surgery. Researchers want to see if this precise type of radiation can control the cancer while causing fewer side effects than standard radi…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This Phase 3 trial tests whether adding a targeted radiation drug (lutetium-177 rosopatamab) to standard care can help men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The study will enroll 520 men across multiple countries. Par…

This Phase 3 trial tests whether adding the chemotherapy drug docetaxel to the standard treatment (apalutamide plus hormone therapy) can help men with metastatic hormone-sensitive prostate cancer who did not have a strong initial response to apalutamide alone. About 320 men will …

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …

This Phase III trial is testing whether using PET scans to guide treatment can help men whose prostate cancer has returned after surgery. For those without signs of spread outside the pelvis, researchers are adding a drug called apalutamide (plus other hormones) to standard radia…

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This study tests whether curcumin, a natural compound found in turmeric, can slow or stop the progression of low-risk prostate cancer in men who are not receiving immediate treatment. About 291 men with early-stage prostate cancer will take either curcumin or a placebo daily for …

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This phase 2 trial is testing three different drugs—abiraterone acetate, enzalutamide, and apalutamide—in 192 veterans with castrate-sensitive prostate cancer that has spread. The goal is to see which drug works best as a first treatment when combined with hormone therapy. Resear…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This study tests whether a new type of radiation seed, called DaRT, can be safely placed inside the prostate to treat cancer that has returned after initial treatment. Up to 10 men with non-metastatic, locally recurrent prostate cancer will receive the seeds. The main goal is to …

This Phase 3 trial is testing whether adding pelvic radiotherapy to standard hormone therapy can delay cancer progression in men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. About 372 participants will be randomly assigned to receive eith…

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This phase 2 trial tests a combination of hormone therapy (Lupron), an androgen blocker (Darolutamide), and an immunotherapy (Pembrolizumab) given before and after prostate removal surgery in 40 men with high-risk prostate cancer. The goal is to see if this approach can reduce or…

This study tests darolutamide, a drug that blocks male hormones fueling prostate cancer, in Indian men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). All 50 participants will take darolutamide pills twice a day along with standard hormone therapy. Th…

This phase 2 trial is testing whether combining focal prostate ablation (a surgery that destroys only the cancerous part of the prostate) with a short course of hormone therapy can effectively treat intermediate-risk prostate cancer. The study will enroll 57 participants and meas…

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This phase 2 trial is testing a drug called ivonescimab in 24 people with advanced cutaneous squamous cell carcinoma (a type of skin cancer) or castration-resistant prostate cancer. The goal is to see if the drug can help control the cancer and to check for side effects. Particip…

This study tests a new drug called AZD0516, given alone or with other cancer drugs, in people with metastatic prostate cancer that has spread. The main goals are to check safety, find the best dose, and see early signs of tumor control. About 177 participants will take part acros…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This registry tracks 2,500 men with prostate cancer who receive Vanquish therapy, a procedure that uses water vapor (steam) to destroy cancerous tissue. The goal is to see how well it controls the disease and what side effects occur over time in real-world settings. Participants …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study is testing a new type of radiation therapy for early-stage prostate cancer that delivers very high doses in just a few sessions. The radiation machine adjusts the beam daily based on the patient's anatomy, aiming to protect healthy tissue. Researchers will track qualit…

This early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This study tests a procedure called irreversible electroporation (IRE) using the NanoKnife system to treat intermediate-risk prostate cancer. The goal is to destroy cancer cells with fewer side effects than standard treatments like surgery or radiation. About 100 men over age 50 …

This study tests a new treatment for people with metastatic breast or prostate cancer that has stopped responding to standard therapies. Participants receive infusions of their own immune cells that have been armed with a special antibody to help them find and attack cancer cells…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This early-phase study tests a new combination of two drugs that deliver radiation directly to prostate cancer cells. The goal is to find the safest dose that can be given together. About 42 men with advanced prostate cancer that has stopped responding to hormone therapy will tak…

This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…

This study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…

This early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…

This Phase 3 trial tests whether adding a radioactive drug called AAA817 to standard hormone therapy can slow cancer growth better than current treatments alone. About 940 men with PSMA-positive metastatic castration resistant prostate cancer will be randomly assigned to receive …

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This phase 2 study is testing whether adding talazoparib to standard hormone therapy and enzalutamide can help men with prostate cancer that has spread to lymph nodes. About 30 participants will take the drug combination before having their prostate removed. The goal is to see if…

This phase 3 trial tests a radioactive drug called lutetium-177 vipivotide tetraxetan in 450 men whose prostate cancer has returned and spread to a few spots after initial treatment. The drug targets a protein on cancer cells and delivers radiation directly to them. The goal is t…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study tests whether high intensity focused ultrasound (HIFU) can control prostate cancer that has come back after radiation therapy. About 25 men will receive one session of HIFU using the Focal One device. Researchers will check if the cancer remains absent in the treated a…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This phase II trial is testing whether adding two hormone-blocking drugs, relugolix and enzalutamide, to standard radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if it lowers the…

This early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combin…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radi…

This Phase 3 trial tests whether adding pasritamig, a drug that directs the body's T-cells to attack prostate cancer cells, to standard chemotherapy (docetaxel) can slow cancer growth better than chemotherapy alone. The study involves 800 men with metastatic castration-resistant …

This study tests a new treatment called AB-3028, which uses a patient's own immune cells (T cells) that have been modified in a lab to better attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to ho…

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and del…

This study tests a new drug called INV-9956 in 84 men with advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants take INV-9956 al…

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The first drug helps the immune system attack cancer cells, and the second aims to make the immune system work bet…

This early-phase study is testing a new drug called pasritamig (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose. About 300 participants will be …

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This phase 3 study tests a drug called pasritamig, which helps the body's immune T-cells attack prostate cancer cells. The trial includes 663 men with metastatic castration-resistant prostate cancer, a stage where standard hormone therapy no longer works. Participants receive eit…

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This early-phase study tests two experimental drugs (JNJ-87189401 and JNJ-78278343) that help the immune system attack prostate cancer cells. The study involves about 355 men with advanced prostate cancer. The main goal is to find the safest dose and check for side effects.

This study follows 700 adults with prostate cancer who have already received at least one dose of lutetium-177 PSMA-617 in earlier Novartis trials. Researchers will monitor long-term side effects such as dry mouth, eye dryness, bone marrow problems, kidney damage, and new cancers…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a laser treatment guided by MRI to destroy early-stage prostate cancer in men aged 40-80 with low to intermediate risk. The goal is to control the cancer and avoid more aggressive treatments like surgery or radiation. Researchers will check results with follow-up…

This study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…

This study looks at whether metformin, a drug used for diabetes, can help prostate cancer patients who have high blood sugar or are overweight. About 100 men will either take metformin plus get lifestyle advice, or just get lifestyle advice. The main goal is to see if it's possib…

This study tests a next-generation radiation therapy (SABR) for men with low to high-risk prostate cancer. The goal is to see if this advanced technique can control the cancer while reducing long-term side effects like urinary and bowel problems. About 136 participants will recei…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This study tests whether taking creatine supplements along with a home-based resistance training program can help men with metastatic prostate cancer maintain muscle mass and reduce fatigue. Two hundred participants will be randomly assigned to receive either creatine or a placeb…

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase study tests a new radioactive drug (161Tb-PSMA-I&T) in 12 Taiwanese men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The drug seeks out prostate cancer cells and delivers targeted radiation. The main goal is…

This study tests several new drug combinations for men with advanced prostate cancer that has spread. The experimental drugs include QLC5508 (a targeted therapy that delivers a toxin to cancer cells) and QLH12016 (a drug that breaks down the male hormone receptor). These are comb…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-phase trial is testing a new treatment called A-CAR032 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer …

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This study tests whether freezing only the part of the prostate that contains cancer (focal cryotherapy) can control intermediate-risk prostate cancer. About 30 men with a single area of cancer will receive this targeted treatment. The goal is to reduce side effects while keeping…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This early-phase study tests whether combining a radioactive drug (177Lu-PSMA-617) with liver-directed procedures (ablation or chemoembolization) is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. The 30 participants must have alrea…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has worsened despite prior treatments. The goal is to see if the combination can shrink tumors, lower PSA levels, or keep the cancer stable for a…

This study tests whether adding precise, high-dose radiation to cancer spots outside the prostate (called metastases) can help men whose prostate cancer has spread to just a few places. About 122 men with up to 5 metastatic spots will receive standard treatment plus either observ…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This study follows 500 men in Germany with metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide plus standard hormone therapy. Researchers will check how many have very low PSA levels after 12 months and track survival and health over 5 years. The goal…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This early-stage study tests a new drug called AMG 509, alone or with other medicines, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the body processes the drug. About 479 participants will…

This Phase II trial tests two experimental drugs, JS212 and JS213, alone or together, in 410 adults with advanced solid tumors (kidney, prostate, bladder, or skin cancer). The main goal is to see if the drugs shrink tumors. Researchers will also check safety and how long any bene…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. TD001 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to prostate cancer cells that have a specific marker (…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This early-phase trial is testing a new radioactive drug called FL-020 in 50 men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to seek out and deliver radiati…

This trial is testing whether combining the drug Pluvicto with precise radiation (SBRT) can lower the chance of cancer returning in men with locally advanced prostate cancer, while also reducing the need for long-term hormone therapy. About 45 participants will receive one to thr…

This study tests an experimental drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has worsened after prior treatments, including a targeted therapy. About 443 participants will be randomly assigned to receive either AAA817 or the …

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This study tests whether a special PET-MRI scan using a radioactive tracer called rhPSMA-7.3 can find higher-risk prostate cancer that standard tests might miss. Men with low-risk or favorable intermediate-risk prostate cancer who are candidates for active surveillance will recei…

This trial tests whether a special PET/CT scan using a tracer called POSLUMA can detect prostate cancer in men whose PSA levels are rising after treatment but who had negative results on standard PET scans. The study enrolls men with biochemical recurrence and low PSA levels. Res…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans an…

This study tests a new radioactive tracer called [18F]FluorThanatrace (FTT) used with PET/CT scans to measure PARP-1 activity in men with metastatic prostate cancer. Up to 30 participants will have scans before and after starting a new therapy. The goal is to see if FTT can non-i…

This study tests whether an artificial intelligence (AI) algorithm can help doctors decide where to take biopsy samples in men with prostate MRI findings that are not clearly cancerous. About 50 men with low-risk or uncertain MRI lesions and elevated PSA levels will be randomly a…

This study tests whether men with very high PSA and suspicious MRI can safely skip the painful 12-needle systematic biopsy and rely only on targeted samples. Over 1,200 men will get both biopsies, but each sample is analyzed separately to see how often the extra needles find dang…

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…

This study investigates whether a blood test (liquid biopsy) can detect prostate cancer early by looking for tumor cells and genetic material in the blood. Researchers will compare blood samples from men with suspected prostate cancer to those without the disease. The goal is to …

This early-stage trial tests whether a special nanoparticle tracer can help surgeons see prostate cancer cells during surgery. Sixteen men with high-risk prostate cancer will receive an injection of the tracer, then undergo PET/MRI scans and surgery. The goal is to see if the tra…

This early-stage study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to see if it is safe and can help detect cancer that has spread or come back. Participants receive one injection and then undergo PET scans to measure rad…

This study tests a new imaging method called FAPI PET/MRI to see if it can find and track prostate cancer that has spread better than current scans. About 30 adults with prostate cancer will get two research scans. The goal is to improve how doctors detect and monitor the disease…

This study tests a new imaging approach for people with advanced breast or prostate cancer. It uses two radioactive tracers to find tumors that have a specific protein (GRPR). The goal is to see if this method is safe and can help doctors see where the cancer is in the body. Abou…

This study tests whether a newer biopsy method (perilesional biopsy) can find aggressive prostate cancers as well as the standard combination of targeted and systematic biopsies. About 640 men with a single suspicious MRI lesion will be randomly assigned to one of two biopsy appr…

This study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be co…

This study compares two biopsy methods in 572 men who have multiple suspicious spots on MRI but have never had a prostate biopsy. One method combines targeted biopsy with a wider sampling around each spot (perilesional biopsy), while the other combines targeted biopsy with standa…

This study at Mayo Clinic is testing whether a special ultrasound technique called vibroelastography can better assess erectile function recovery in men after prostate cancer surgery. The technique measures tissue stiffness, which may indicate scarring. Ten men with low-risk pros…

This study tests whether combining two advanced imaging techniques (micro-ultrasound and MRI) during prostate biopsy can find more aggressive cancers than the current standard approach. About 400 men with suspected prostate cancer will participate. The goal is to improve detectio…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…

This study compares a newer PSMA PET scan to the standard MRI for staging prostate cancer in men eligible for focal therapy (treatment that targets only the tumor). About 138 men with early-stage prostate cancer will be randomly assigned to get the PSMA PET scan or not. The goal …

This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…

This study is testing whether an artificial intelligence (AI) model can accurately predict which prostate cancers are aggressive and need treatment. Researchers will combine MRI and ultrasound images with tissue samples from 3,000 men. The goal is to reduce unnecessary biopsies a…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study tests whether using a special scan (PSMA PET/MRI) to guide prostate biopsies can find cancers that standard methods miss. It includes 230 men with elevated PSA, at least one prior negative biopsy, and low-risk MRI results. The goal is to improve early detection of clin…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This study is for men with low- to intermediate-risk prostate cancer. It compares giving a lower radiation dose to some parts of the prostate versus the same dose to the whole prostate. The goal is to see if the lower dose reduces short-term urinary side effects. About 54 people …

This phase III trial tests whether an automated planning tool called RapidPlan can match or beat human-driven planning for prostate cancer radiation therapy. About 108 men with prostate cancer will be randomly assigned to one of two planning methods. The goal is to see if the aut…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This study looks at whether taking creatine supplements while doing supervised weight training for 12 weeks can help men with prostate cancer who are on hormone therapy (ADT) maintain or improve their muscle mass, strength, and physical function. ADT often causes muscle loss and …

This study tests a web-based program called TEMPO designed to help men with prostate cancer and their caregivers cope with anxiety and improve physical activity. About 376 patient-caregiver pairs will be randomly assigned to use TEMPO or simply monitor their anxiety for 12 weeks.…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study tests if a newer, more precise type of radiation (adaptive SBRT) can cause fewer urinary problems than standard radiation for men with localized prostate cancer. About 320 men will be randomly assigned to one of the two radiation methods. The goal is to see if the newe…

This study tests whether a supervised golf exercise program can improve physical function, mental health, and quality of life in prostate cancer survivors who are on hormone therapy. Twenty men aged 55-85 with little or no golf experience will participate. The program includes wa…

This study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…

This study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. T…

This study tests whether a rectal indomethacin suppository given right after surgery can prevent or reduce bladder discomfort caused by a urinary catheter in men undergoing laparoscopic radical prostatectomy. About 130 participants will be randomly assigned to receive either the …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study tracks 500 men aged 30-75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly exams, blood tests, and MRI scans to understand how these genes affect cancer risk. The goal …

This study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …

This study looks at whether a special MRI scan (mpMRI) can better monitor prostate cancer in men who choose active surveillance instead of immediate treatment. About 500 men with low-risk prostate cancer will get regular MRIs, biopsies, and blood tests over several years. The goa…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study explores whether a 7-day water-only fast or ketone supplements are safe and doable for men with prostate cancer. The idea is that fasting may change the body's metabolism and boost immune cells to better attack cancer. Researchers will track side effects and how many p…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study looks at heart-related side effects in older men with advanced prostate cancer treated with enzalutamide or darolutamide. Researchers will analyze existing health records from 3,000 men aged 55 and older to compare rates of heart attacks, strokes, and heart-related dea…

This study tests whether a short video can help more minority patients with prostate cancer join clinical trials. Researchers at LBJ Hospital will show the video to 60 patients and ask them questions before and after. The goal is to find a simple way to make cancer research more …

This study tests an artificial intelligence (AI) tool designed to help doctors and physicists review radiation treatment plans for cancer patients before therapy begins. The AI highlights differences in how providers plan treatments and flags potential warning signs, aiming to re…

This study aims to help African American cancer survivors learn about and get genetic testing for hereditary cancer risks. Researchers are adapting an online educational program to be culturally relevant, with input from community leaders and genetics experts. About 85 participan…

This study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…

This study follows 2,000 men with prostate cancer who have certain gene mutations. Researchers will track their health over many years to see how these genes relate to cancer growth, treatment response, and survival. Participants do not need to visit the hospital regularly; most …

This observational study will follow 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect medical records to see how many men achieve very low PSA leve…

This study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.

This study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…

This study compares two imaging methods—micro-ultrasound and MRI—for monitoring prostate cancer in men on active surveillance. Researchers will perform biopsies guided by each technique to see which better detects cancer progression. The goal is to determine if micro-ultrasound c…

This study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effect…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study analyzes anonymous prescription records from Australian databases to see how men with advanced prostate cancer are actually treated. Researchers will look at which drugs are used, patient ages, and how well people stick to their medication. The goal is to learn from re…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…

This study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to und…

This study looks at whether special breathing exercises can help the brains of people with multiple sclerosis or cancer, as well as their caregivers. Researchers will use MRI scans to see how breathing affects oxygen flow in the brain. The goal is to understand the connection bet…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This registry gathers real-world information from thousands of men treated with high-intensity focused ultrasound (HIFU) for prostate cancer using the Focal One device. The goal is to monitor safety and track cancer control through routine PSA tests and MRI scans. By collecting d…

This study tests whether a questionnaire can help doctors spot side effects early in people who have finished treatment for breast or prostate cancer. About 200 survivors will either use the questionnaire or receive standard care. The goal is to see if active monitoring improves …

This study is looking for better ways to detect prostate cancer early in men who have a high genetic risk. Researchers will test urine samples and PSA levels in 200 men aged 35-70 with certain gene mutations. The goal is to see if these tests can predict aggressive prostate cance…

This study looks at how the pressure settings on a breathing machine during robot-assisted prostate surgery affect the lungs afterward. Researchers will use lung ultrasound to check for changes in lung health. The goal is to find better ways to set the breathing machine to protec…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study is looking at how common low vitamin D levels are among Black men with prostate cancer, and whether vitamin D supplements can improve their immune function. Researchers will measure vitamin D and immune markers in blood samples before and after supplementation. The goa…

This study looks at how much fluid patients should receive during robotic prostate surgery. It compares a standard approach with a more restricted one, using a non-invasive heart monitor to guide decisions. The goal is to see which method keeps tissues better perfused, measured b…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This study looks at whether men with prostate cancer who have hot flashes from hormone therapy will consistently wear a smartwatch to track their symptoms. For 4 weeks, 18 participants will wear the watch, log hot flashes by pressing a button, and complete daily surveys. The goal…

This study is for people with advanced prostate cancer that has spread to bones or lymph nodes and is no longer responding to standard treatments. Researchers want to find the largest total volume of cancer spots that can be safely treated with a precise type of radiation called …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study is collecting prostate cancer tissue from 16 men with metastatic prostate cancer to analyze the tumor microenvironment—the cells and structures around the tumor. Researchers will use advanced genetic and molecular tests to understand how the immune system interacts wit…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study is figuring out what normal PSA levels are for trans women and non-binary people who have a prostate. Researchers will measure PSA in 500 volunteers aged 40 and older who are on hormones or have had lower surgery. The goal is to help doctors better detect prostate canc…

This study tracks 270 men with metastatic hormone-sensitive prostate cancer to see how faithfully they take their apalutamide pills over the first year. Researchers will use questionnaires to measure adherence and identify who is at risk of skipping doses. The goal is to learn wh…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigat…

This study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study follows 300 men with metastatic castration-resistant prostate cancer who are taking olaparib in everyday medical practice. Researchers will track how long patients stay on the drug, how well it controls the cancer, and any side effects. The goal is to learn how olapari…

This study follows 278 men with advanced prostate cancer who are already receiving Pluvicto as part of their routine care in South Korea. Researchers will monitor side effects and how well the drug controls the cancer over time. No new treatment is given—this is purely an observa…

This study is a registry that collects information from 1,000 men with prostate cancer who receive focal therapy using high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE). No new treatment is given—researchers simply record patient details, disease feat…

This study follows 500 men with metastatic castration-resistant prostate cancer who are receiving lutetium-177 vipivotide tetraxetan (a radioactive drug) as part of their routine care. Researchers will measure quality of life, pain, and disease progression over time using patient…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at how well a telehealth program called National TeleOncology works for veterans newly diagnosed with lung, colorectal, prostate, or breast cancer. Researchers will track how many veterans use telehealth visits and whether the program affects the quality of care …

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoidin…

This study follows 106 men who have had surgery for prostate cancer to see how well they recover bladder control, sexual function, and overall health. Participants will receive standard care plus optional exercise programs. The goal is to better understand recovery timelines and …

This study brings together a panel of prostate cancer specialists to agree on the most important pieces of information that should be included in medical records. The goal is to create a standard way to report key data, making it easier for doctors to manage patients from diagnos…